Lv1
30 积分 2021-08-19 加入
Efficacy assessment in phase I clinical trials: endpoints and challenges
4小时前
已完结
Preferential tumor targeting of HER2 by iPSC-derived CAR T cells engineered to overcome multiple barriers to solid tumor efficacy
4小时前
已完结
Accelerating and optimising CAR T-cell manufacture to deliver better patient products
6天前
已完结
Epigenetic Landscapes Drive CAR-T Cell Kinetics and Fate Decisions: Bridging Persistence and Resistance
8天前
已完结
Armored Bicistronic CAR T Cells with Dominant-negative TGF-β Receptor II to Overcome Resistance in Glioblastoma
10天前
已关闭
Surgical considerations for tumour-infiltrating lymphocyte therapy in melanoma: results from a randomized phase III trial
13天前
已关闭
Tuning the Antigen Density Requirement for CAR T-cell Activity
14天前
已完结
CAR Binders Affect CAR T-cell Tonic Signaling, Durability, and Sensitivity to Target
15天前
已完结
Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial
18天前
已完结
Pancreatic cancer-restricted cryptic antigens are targets for T cell recognition
22天前
已完结
皖公网安备34019202002308
